|Healthcare Review: Acorda Therapeutics Inc, Utah Medical Products, Cytori Therapeutics, Cadence Pharmaceuticals, Johnson & Johnson|
|By Staff and Wire Reports|
|Tuesday, 16 April 2013 13:52|
Following are notable movers at mid day on Tuesday:
Acorda Therapeutics Inc. (NASDAQ:ACOR) stock jumped 9.53% to $38.88. The company, on April 15, announced that a proof-of-concept trial found dalfampridine extended release (ER) tablets, marketed as AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, improved walking in people with post-stroke deficits. Post-stroke deficits refer to chronic neurological deficits, such as impaired walking, motor and sensory function and manual dexterity that persist in people who have had a stroke.
Utah Medical Products, Inc. (NASDAQ:UTMD) stock fell 0.87% to $42.26. The 52 week trading range for the company is $29.66 - $49.85. The company is in the business of producing medical devices that are, disposable and for hospital use. The Company markets a range of medical devices used in critical care areas, especially the neonatal intensive care unit (NICU), the labor and delivery (L&D) department and the women's health center in hospitals, as well as products sold to outpatient clinics and physician's offices.
Cytori Therapeutics Inc. (USA) (NASDAQ:CYTX) stock jumped 7.66% to $2.53. Zacks upgraded shares of Cytori Therapeutics (NASDAQ: CYTX) from a neutral rating to an outperform rating in a research report released on April 11. Zacks currently has $3.00 price target on the stock.
Additionally, the company on Mar. 28, received US Patent No. 8,404,229 (the '229 patent) for methods of treating renal diseases using adipose-derived regenerative cells (ADRCs). The '229 patent covers treatment of a broad range of renal disorders, including acute kidney disease (AKD) and chronic kidney disease (CKD).
Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) shares increased 6.61% to $6.94 in the early hour. JMP Securities initiated coverage on shares of Cadence Pharmaceuticals in a research report sent to investors on April 1. The firm issued an outperform rating and a $8.00 price target on the stock. Additionally, analysts at DA Davidson downgraded shares of Cadence Pharmaceuticals from a buy rating to a neutral rating in a research note to investors on March 12.
Johnson & Johnson (NYSE:JNJ) shares increased 1.80% to $83.18. The company today said it beat Wall Street's quarterly profit estimates on sharply lower taxes, strong sales of prescription drugs and a revival of over-the-counter medicines that had been recalled over quality control problems.